@thepatientinvestorr
YouTube
Avg. Quality
69
Success Rate
24.32
Analysis
222
Correct
54
Fail
118
Pending
44
Ineffective
0
Total Quality
Score
If You Had Traded on This Analysis…
Fail
NVO
Long Entry
38.5850
2026-03-07
22:01 UTC
Target
40.0000
Fail
37.0000
In 1 Weeks
Risk/Reward
1 : 1
Turn Signals into Profit
Join Tahlil Plus Pro to unlock full performance history, live alerts, and AI-backed risk tools.
Start Free
Final PnL
-4.11%
P/L: —
Turn Signals into Profit
Join Tahlil Plus Pro to unlock full performance history, live alerts, and AI-backed risk tools.
Start Free
The speaker discusses a potential partnership between Novo Nordisk (NVO) and Hims & Hers Health Inc. (HIMS) to sell obesity drugs. While HIMS saw a significant price surge on this news, the speaker remains skeptical, citing it as a Bloomberg story from a single reporter and drawing parallels to past instances where similar rumors led to stock downturns. The speaker notes that NVO's financial performance is not as strong as HIMS', but the partnership could be beneficial for HIMS by expanding its market reach and potentially boosting its stock. The speaker also mentions that HIMS was not included in a recent FDA warning about compounded GLP-1s, which might be a positive sign.
